CDKN2A and hepatocellular carcinoma: Our findings suggested that high levels of CDKN2A, BIRC5, and SPP1 were associated with poor overall survival in patients with HCC, suggesting that BIRC5, CDKN2A, and SPP1 are associated with HCC progression and could be used as tumor biomarkers in patients with HCC.